Nath Bio-Genes (India) Ltd. (NATHBIOGEN) AI Stock Analysis

• Market Cap: ₹3.33B
• Dividend Yield: 1.13%
• Average Volume (3M): 7.08K
• Price to Earnings (P/E): 8.3
• Beta (1Y): 1.31
• Revenue Growth: 18.61%
• EPS Growth: 4.02%
• Country: IN
• Employees: 423
• Sector: Consumer Defensive
• Sector Strength: 61
• Industry: Agricultural Inputs
• EPS (TTM): 18.53
• Shares Outstanding: 19,004,000
• 10 Day Avg. Volume: 2,089
• 30 Day Avg. Volume: 7,082
• PEG Ratio: -1.64
• Price to Book (P/B): 0.47
• Price to Sales (P/S): 0.82
• P/FCF Ratio: 31.02
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹203.00
• Price Target Upside: 15.31% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 61 Neutral
• Price Target: ₹203.00 ▲(15.31% Upside)

Nath Bio-Genes has a strong financial foundation and attractive valuation, but the technical indicators reveal bearish momentum. The overall score reflects a balance between solid financial health and current negative market sentiment.

Nath Bio-Genes (India) Ltd. Business Overview & Revenue Model

Company Description

Nath Bio-Genes (India) Ltd. (NATHBIOGEN) is an Indian agricultural biotechnology company that specializes in the research, development, production, and marketing of hybrid and genetically modified seeds. The company operates primarily in the agribusiness sector, providing high-yielding seeds for a variety of crops including cotton, paddy, maize, and various vegetables, with a focus on enhancing agricultural productivity and sustainability.

How the Company Makes Money

Nath Bio-Genes (India) Ltd. makes money primarily through the sale of its proprietary hybrid and genetically modified seeds to farmers and agricultural businesses. The company's revenue streams are driven by its extensive research and development initiatives that lead to the creation of high-yield and disease-resistant seed varieties. Nath Bio-Genes also engages in strategic partnerships and collaborations with research institutions and agricultural organizations to enhance its product offerings and market reach. Additionally, the company invests in marketing and distribution networks to ensure its seeds are widely available across India and potentially other markets, contributing to its earnings.

Nath Bio-Genes (India) Ltd. Financial Statement Overview

Summary

Nath Bio-Genes has a strong profitability profile with healthy profit margins and revenue growth. The balance sheet shows financial stability with low debt and improved return on equity. However, there is variability in EBIT, EBITDA margins, and free cash flow, which could impact liquidity.

Income Statement

The company shows a solid performance in terms of profitability with a healthy gross profit margin and stable net profit margin. Revenue growth from 2024 to 2025 was significant, indicating a positive trajectory. However, EBIT and EBITDA margins have shown slight fluctuations over the years, suggesting some variability in operating efficiency.

Balance Sheet

Nath Bio-Genes maintains a strong equity base with a relatively low debt-to-equity ratio, indicating financial stability. The return on equity has improved, reflecting effective use of shareholder funds. However, the equity ratio indicates a moderate reliance on debt, which could pose risks if not managed carefully.

Cash Flow

The cash flow statement reflects a positive trend in free cash flow growth, indicating improved cash generation from operations. The operating cash flow to net income ratio suggests efficient conversion of income into cash. However, the free cash flow to net income ratio has shown variability, which may affect liquidity.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.65B	3.65B	2.48B	3.01B	2.78B	3.07B
Gross Profit	1.82B	2.29B	1.03B	1.67B	1.54B	1.71B
EBITDA	500.95M	497.98M	536.39M	488.91M	-497.06M	684.33M
Net Income	386.00M	386.00M	396.19M	350.11M	-673.38M	556.62M
Balance Sheet
Total Assets	10.26B	10.26B	8.80B	7.93B	7.42B	7.90B
Cash, Cash Equivalents and Short-Term Investments	888.99M	888.99M	774.10M	2.09B	41.68M	292.11M
Total Debt	1.23B	1.23B	1.10B	1.05B	929.59M	965.67M
Total Liabilities	3.82B	3.82B	2.70B	2.20B	2.00B	1.76B
Stockholders Equity	6.44B	6.44B	6.10B	5.73B	5.42B	6.13B
Cash Flow
Free Cash Flow	0.00	96.61M	478.18M	358.18M	-39.70M	-104.86M
Operating Cash Flow	0.00	175.81M	745.94M	383.67M	170.46M	11.13M
Investing Cash Flow	0.00	-39.62M	-274.01M	-28.84M	-198.66M	-102.82M
Financing Cash Flow	0.00	-21.30M	-77.78M	-16.68M	-222.27M	164.01M

Nath Bio-Genes (India) Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 176.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NATHBIOGEN, the sentiment is Neutral. The current price of 176.05 is below the 20-day moving average (MA) of 177.55, below the 50-day MA of 194.20, and below the 200-day MA of 177.49, indicating a neutral trend. The MACD of -5.61 indicates Negative momentum. The RSI at 43.16 is Neutral, neither overbought nor oversold. The STOCH value of 62.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:NATHBIOGEN.

Nath Bio-Genes (India) Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARIES	71 Outperform	₹5.12B	13.92		0.25%	19.25%	67.58%
HARRMALAYA	69 Neutral	₹3.97B	15.19		―	8.73%	―
Sector *	63 Neutral	$20.95B	14.50	-3.82%	3.12%	2.72%	-11.24%
NATHBIOGEN	61 Neutral	₹3.33B	8.33		1.13%	18.61%	4.02%
NOVAAGRI	58 Neutral	₹4.72B	17.59		―	―	―